Legend Biotech Corporation which can be found using ticker (LEGN) have now 10 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between 90 and 65 with the average target price sitting at $79.90. Given that the stocks previous close was at $68.96 and the analysts are correct then we can expect a percentage increase in value of 15.9%. The 50 day moving average now sits at $58.33 and the 200 moving average now moves to $50.37. The market capitalization for the company is 11.62B. The stock price for Iron Mountain Incorporated is 66.54 USD
The potential market cap would be $13,461,516,407 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 0.64 and a -28.72% return on assets.
Legend Biotech Corporation is a global biotechnology company, which is focused on developing, manufacturing and commercializing novel therapies to treat life-threatening diseases. The Company is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), is a CAR-T cell therapy for the treatment of multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also developing an allogeneic gamma delta CAR-T product candidate targeting B-cell maturation antigen for MM.
